An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of MTL-CEBPA Administered in Combination With Sorafenib in Participants With Hepatocellular Carcinoma (HCC) and Hepatitis B or Hepatitis C Virus (OUTREACH2)
Latest Information Update: 10 Mar 2025
At a glance
- Drugs MTL CEBPA (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms OUTREACH2
- Sponsors MiNA Therapeutics
- 06 Mar 2025 Status changed from active, no longer recruiting to completed.
- 24 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 04 Jan 2023 This trial has been suspended in Sweden, according to European Clinical Trials Database record.